Who founded Engimmune Therapeutics?

Engimmune Therapeutics was founded by Rodrigo Vazquez-Lombardi, Sai Reddy in 2021.

Who are Engimmune Therapeutics's investors?

Engimmune Therapeutics's investors include Pureos Bioventures, Novo Holdings.

Engimmune Therapeutics

Founded 2021 · 12 employees on LinkedIn · 2 known investors

Find your way into Engimmune Therapeutics

Each arrow is one introduction. Sign up to fill in the first one.

161 people can intro you to Rodrigo

Ask Jørgen Søberg Petersen to introduce you to Rodrigo Vazquez-Lombardi

You →Jørgen · together at Engimmune Therapeutics →Rodrigo

Your email: who you already know at Engimmune Therapeutics, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Engimmune Therapeutics team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Engimmune develops soluble TCR therapeutic candidates using AI-guided innovation and protein engineering for oncology and immunotherapy applications. The company was founded by veteran biotherapeutics developers and focuses on unlocking therapeutic potential through its differentiated technology platform.

AI & Machine Learning Biotech Deep Tech

Founders & leadership

Engimmune Therapeutics was founded in 2021 by Rodrigo Vazquez-Lombardi and Sai Reddy.

Rodrigo Vazquez-Lombardi Rodrigo Vazquez-Lombardi is a protein engineer and immunologist with over a decade of experience developing engineered cancer immunotherapies across antibody, cytokine, and cellular modalities. He is co-founder of Engimmune Therapeutics, which develops soluble TCR therapeutic candidates for oncology and immunotherapy applications.

Sai ReddyFounder

Investors · 2

Pureos Bioventures✓ confirmed by Engimmune TherapeuticsPfäffikon

How we know: Pureos Bioventures's portfolio page · the company's own site · a partner's Signal profile · Not right? Tell us

Novo Holdings✓ confirmed by Engimmune TherapeuticsCopenhagen · $1.1M – $54M

How we know: the company's own site · Not right? Tell us

Funding

SEC filings, press & company announcements

Undisclosed amountSeedMay 2022
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Frequently asked questions

What does Engimmune Therapeutics do?: Engimmune develops soluble TCR therapeutic candidates using AI-guided innovation and protein engineering for oncology and immunotherapy applications. The company was founded by veteran biotherapeutics developers and focuses on unlocking therapeutic potential through its differentiated technology platform.
Who founded Engimmune Therapeutics?: Engimmune Therapeutics was founded by Rodrigo Vazquez-Lombardi, Sai Reddy in 2021.
Who are Engimmune Therapeutics's investors?: Engimmune Therapeutics's investors include Pureos Bioventures, Novo Holdings.